Sign in
1121 Tigilanol tiglate is a naturally occurring small molecule oncolytic that effectively ablates tumors via intratumoural injection and can enhance response to immune checkpoint blockade
Abstract   Open access   Peer reviewed

1121 Tigilanol tiglate is a naturally occurring small molecule oncolytic that effectively ablates tumors via intratumoural injection and can enhance response to immune checkpoint blockade

Jason Cullen, Pei-Yi Yap, Blake Ferguson, Zara Bruce, Motoko Koyama, Herlina Handoko, Jacinta L Simmons, Jenny Johns, Marjorie D'Souza, Natasa Broit, …
Journal for ImmunoTherapy of Cancer, Vol.10(Supplement 2), pp.A1165-A1165
Society for Immunotherapy of Cancers (SITC) Annual Meeting, 37th (Boston, United States, 08-Nov-2022–12-Nov-2022)
2022
pdf
A1165.full71.17 kBDownloadView
Published Version Open Access
url
http://dx.doi.org/10.1136/jitc-2022-SITC2022.1121View
Published Version

Abstract

No abstract available.

Details

Metrics

6 File views/ downloads
88 Record Views

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
International collaboration
Web Of Science research areas
Immunology
Oncology

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Logo image